Durogesic DTrans should only be used in patients who have demonstrated opioid tolerance.
The initial dose should be based on the patient’s opioid history, including the degree of opioid tolerance, if any, as well as on the current general condition and medical status of the patient.
In strong opioid-naïve patients, treatment should be initiated with the 25 microgram per hour patch.
Clinical experience is limited in opioid-naïve patients. If therapy is considered appropriate in these patients, titrate with low doses of short-acting opioids before converting to Durogesic DTrans 25 microgram per hour.
Further information: Janssen-Cilag Ltd